SCHEMBL131786

SCHEMBL131786

O=C(Nc1ccc(O)c(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1)c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 14/20 0.74
P2RX4 Q99571 4/20 0.69
P2RX7 Q99572 4/20 0.69
TMPRSS4 Q9NRS4 9/20 0.66
MEN1 O00255 1/20 0.64
IKBKB O14920 1/20 0.64
CHUK O15111 1/20 0.64
KDR P35968 1/20 0.64
FLT3 P36888 1/20 0.64
KMT2A Q03164 1/20 0.64
MYLK Q15746 1/20 0.64
MAP4K5 Q9Y4K4 1/20 0.64
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
RXFP1 Q9HBX9 1/20 0.59
SLC2A1 P11166 1/20 0.57
TRPA1 O75762 1/20 0.57
CYP1A2 P05177 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130063 0.89 P2RX1 (0.67) P2RX1P2RX4P2RX7TMPRSS4MEN1
SCHEMBL131395 0.86 P2RX1 (0.64) P2RX1P2RX4P2RX7TMPRSS4MEN1
SCHEMBL23447713 0.86 P2RX1 (1.00) P2RX1P2RX4P2RX7NPC1RAB9A
SCHEMBL29781402 0.86 P2RX1 (0.67) P2RX1P2RX4P2RX7TMPRSS4MEN1
SCHEMBL23388964 0.86 P2RX1 (0.67) P2RX1P2RX4P2RX7TMPRSS4MEN1
SCHEMBL130439 0.85 P2RX1 (0.81) P2RX1P2RX4P2RX7TMPRSS4MEN1
SCHEMBL14886087 0.84 P2RX1 (0.71) P2RX1P2RX4P2RX7TMPRSS4MEN1
SCHEMBL3497707 0.84 P2RX1 (0.64) P2RX1P2RX4P2RX7TMPRSS4MEN1
SCHEMBL131701 0.83 P2RX1 (0.71) P2RX1P2RX4P2RX7TMPRSS4MEN1
SCHEMBL131927 0.83 P2RX1 (0.72) P2RX1P2RX4P2RX7TMPRSS4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
EP-1844766-B1 Inhibitors against the production and release of inflammatory cytokines INST MED MOLECULAR DESIGN INC (JP) 2012-04-18 EP disclosed
EP-1352650-B1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES INST MED MOLECULAR DESIGN INC (JP) 2012-03-07 EP disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-12-25 US disclosed
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-10-09 US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A P2RX1 1459/4885P2RX4 2669/4885P2RX7 928/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A P2RX1 1538/4885P2RX4 2695/4885P2RX7 973/4885
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A P2RX1 1538/4885P2RX4 2695/4885P2RX7 973/4885
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A P2RX1 1538/4885P2RX4 2695/4885P2RX7 973/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB P2RX1 2316/4885P2RX4 3466/4885P2RX7 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.